Company profile for AmacaThera

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresse...
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. Currently, we have developed a combination product for post-operative pain

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
661 University Ave, Suite 1300 Toronto, Ontario M5G 0B7
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/amacathera-signs-exclusive-global-licensing-agreement-with-pacira-biosciences-for-up-to-us230-million-validating-its-tunable-drug-delivery-platform-302603911.html

PR NEWSWIRE
04 Nov 2025

https://www.prnewswire.com/news-releases/amacathera-and-merck-animal-health-announce-collaboration-in-animal-health-302443912.html

PR NEWSWIRE
01 May 2025

https://www.prnewswire.com/news-releases/amacathera-collaborates-with-leading-global-pharmaceutical-company-to-develop-single-injection-long-acting-biologic-using-its-advanced-hydrogel-delivery-platform-amacagel-302422309.html

PR NEWSWIRE
08 Apr 2025

https://www.prnewswire.com/news-releases/dr-eyal-s-ron-joins-amacathera-board-of-directors-to-drive-strategic-growth-and-accelerate-innovation-in-long-acting-therapies-302345083.html

PR NEWSWIRE
08 Jan 2025

https://www.prnewswire.com/news-releases/amacathera-announces-phase-1-results-of-first-in-human-study-with-amt-143-exceeding-expectations-and-paving-the-way-for-a-novel-approach-to-post-operative-pain-relief-302310726.html

PR NEWSWIRE
20 Nov 2024
AmacaThera Closes Series A Extension
AmacaThera Closes Series A Extension

28 Nov 2023

// PR NEWSWIRE

https://www.prnewswire.com/news-releases/amacathera-closes-series-a-extension-to-advance-clinical-development-of-long-acting-localized-non-opioid-therapeutics-to-improve-post-surgery-patient-care-301998414.html

PR NEWSWIRE
28 Nov 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty